Health
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial – The Lancet
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients
with NAFLD and constipation. Further studies are necessary to better define the efficacy
and tolerability of lubiprostone in patients with NAFLD without constipation.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
General10 hours agoAlleged Croydon Park gunman Artemios Mintzas charged with 25 offences
-
General23 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania
-
Noosa News17 hours agoPrime Minister Anthony Albanese calls for political temperature to be ‘turned down’ after alleged death threat
-
Noosa News12 hours agoPerth Royal Show attendance slumps to 10-year low